Tuberculosis poses a pressing threat to Tibetan refugee children and adolescents in Indian boarding schools. The alarming reality: 1.8 million Indians suffered from TB in 2022 (WHO), with children under 15 accounting for 12% of reported cases (Central TB Division). To combat this, the pioneering Zero TB Kids Project launched an ambitious screening and preventive […]

Tuberculosis (TB) is one of the most common infections in people living with HIV (PLWHA). TB often strikes people with weakened immune systems, making it a leading cause of death for those with HIV/AIDS. In 2018, about 21% of the 1.2 million global TB deaths were among PLWHA. In South Africa, around 300,000 new TB

Tuberculosis (TB) has emerged as the world’s second deadliest infectious disease, following COVID-19. The COVID-19 pandemic severely impacted TB prevention and treatment efforts, leading to an estimated half a million excess deaths between 2020 and 2022. While there has been some recovery in TB diagnosis and treatment post-pandemic, the disease remains a significant concern, particularly

Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis (MTB), remains a formidable global health challenge. As of 2022, TB was the second leading infectious killer worldwide, claiming 1.3 million lives, following COVID-19. Despite medical advancements, TB continues to pose significant problems due to rising drug resistance and the demands of prolonged treatment regimens. Following a

Tuberculosis (TB) remains a significant global health challenge, ranking among the top ten causes of death worldwide. Despite ongoing efforts, over a million people die from TB each year. Traditional treatment involves a lengthy regimen of antibiotics, but this approach has its drawbacks. Issues such as poor success rates, the rise of drug-resistant strains, and